Regulation A Offering Now Open
Leading The Transition to Better Smoking and Vaping Alternatives
$250 USD Minimum Investment
Cabbacis is a publicly traded company (OTCQB: CABI) developing iBlend™ cigarettes and vaporizer pods with approximately 95 percent less nicotine than leading brands.
iBlend™ predominantly contains very-low-nicotine tobacco with added hemp which is not intoxicating. The result is the best tasting very-low-nicotine tobacco cigarette ever produced. Hemp became legal at the federal level under the 2018 Farm Bill.
Results of many peer-reviewed studies demonstrate that when smokers switch to very-low-nicotine cigarettes, they smoke less, reduce their nicotine exposure and dependence, double their quit attempts, and increase their number of smoke-free days.
Backed by a global patent portfolio including 36 issued patents, the company is positioned to scale within the expanding reduced-risk tobacco category.
$1,000 USD Minimum Investment
iBlend
Built on Patents, Regulation, and Market Demand
Publicly traded on OTCQB under ticker CABI
36 issued patents worldwide (8 is the U.S.) with additional applications pending
Focused on tobacco harm reduction
Products developed within established tobacco regulatory frameworks
Offering type: Regulation A+
Security: Common equity
Share price in offering: $2.00
Minimum investment: $1,000
Industry: Tobacco risk reduction products
Product focus: Very-low-nicotine cigarettes and vaporizer pods
The Opportunity
Why the Smoking Market is Changing
The global tobacco market is undergoing a structural shift. Regulators and manufacturers are increasingly focused on reducing harm while maintaining consumer acceptance
While traditional cigarettes are by far the most popular worldwide tobacco product, many adult smokers are seeking alternatives, especially those that do not require abandoning familiar smoking formats.
This transition is still in its early stages, creating an enormous opportunity for companies positioned with differentiated products and defensible intellectual property.
Focused On Tobacco Harm Reduction
What Cabbacis Does
Cabbacis is a tobacco product manufacturer focused on developing
and commercializing risk-reduction products for adult smokers.
The company’s approach centers on:
Very-low-nicotine tobacco products containing approximately 95% less nicotine than leading brands
Federally legal, non-intoxicating hemp included in products
Familiar cigarette and vaporizer formats
Patented products
The objective is straightforward. Reduce nicotine content while preserving adult consumer acceptance.
The iBlend™ Product Line
Built For Familiarity and Scale
Cabbacis is on the road to commercializing two primary product formats
iBlend™ Cigarettes
Very-low-nicotine cigarettes designed to closely resemble traditional smoking experiences
Significantly lower nicotine content
iBlend™ Vaporizer Pods
Vapor products delivering the same proprietary blend
Modern, regulated format aligned with evolving consumer preferences
Both formats are designed to integrate into existing tobacco distribution and regulatory frameworks.
Why Our Approach Matters
Structural Tailwinds Support Adoption
Increasing regulatory support for reduced-risk products
Growing consumer interest in reduced-risk alternatives
Demand for familiar formats rather than those forcing radical behavioral changes
Limited competition due to company’s patented products
Cabbacis operates where regulation, consumer demand, and innovation intersect.
Intellectual Property
A Defensible Patent Portfolio
Cabbacis holds a substantial global intellectual property position, including:
36 issued patents worldwide including 8 U.S. patents
Multiple pending patent applications
Protection across cigarette and vaporizer pod products
This patent base supports long-term differentiation, licensing potential, and strategic flexibility.
Market Opportunity
A Huge Market in Transition
Tobacco and nicotine products represent a $1 trillion annual global market.
As harm-reduction initiatives gain momentum, even a modest adoption of alternative products represents a meaningful revenue opportunity.
Cabbacis is positioned to participate in this shift without relying on mass behavioral change.
Product And Commercialization Roadmap
A Clear Path to Scale
Cabbacis is advancing iBlend™ products through upcoming staged commercialization while expanding its robust patent portfolio.
Near Term
Advance commercialization of iBlend™ cigarettes
Expand manufacturing and supply chain readiness
Continue regulatory engagement and market entry planning
Mid Term
Broaden distribution through strategic partners
Explore worldwide licensing opportunities
Support and expand patent coverage and product variations
Long Term
Scale international market presence
Monetize intellectual property through partnerships and licensing
Build a diversified portfolio of reduced-risk tobacco products
Business Model
Multiple Paths To Growth
The company plans to pursue growth through:
Direct product commercialization
Strategic partnerships
Licensing arrangements
Geographic expansion
Invest in Better Smoking and Vaping Alternatives
Use Of Proceeds
Planned Capital Deployment
Proceeds from the Regulation A offering are expected to support:
Manufacturing and supply chain expansion
Tobacco & hemp plantings
Research and Development
Product commercialization and distribution
Ongoing intellectual property development
General corporate purposes
Investment Highlights
Why Investors Are Paying Attention
Clear focus on tobacco risk-reduction products
Patented and differentiated products
Scalable cigarette and vaporizer formats
Exposure to a regulated category undergoing structural change
Public company transparency
Accessible minimum investment
This offering provides investors the opportunity to participate in an evolving and growing segment of the tobacco market.
get in touch
Let's talk about your investment
Get in touch with the Cabbacis team to learn more about the investment opportunity or to ask any questions you may have. We’re here to help!
Frequently Asked Questions (FAQs)
1. What is Cabbacis?
Cabbacis is a tobacco product manufacturer focused on developing and commercializing risk-reduction products – led by the flagship iBlend™ cigarettes and iBlend™ vaporizer pods which are covered by dozens of worldwide patents.
2. What does the company develop?
Cabbacis primarily develops products containing very-low-nicotine tobacco and hemp that smoke or vape just like conventional products.
3. What is the purpose of these products?
To provide adult consumers with alternatives to traditional tobacco products to help smokers smoke or vape less, reduce nicotine dependence & exposure, and increase quit attempts.
4. What are the key product categories?
Very-low-nicotine cigarettes and vaporizer pods (for heated tobacco products also known as electronic vaporizers - e.g., IQOS®) that contain about 95% less nicotine.
5. What is the primary brand name?
The company’s consumer-facing brand is “iBlend™.”
6. What makes iBlend™ products different?
iBlend™ uses formulations of very-low-nicotine tobacco and hemp for its patented products which offer pleasing taste and sensory characteristics with about 95 percent less nicotine.
7.Are the products currently on the market?
iBlend™ cigarettes have been developed, manufactured and used is studies and focus groups. Commercial sales have not yet begun. iBlend pods are still in the development phase.
8. Are the products regulated as tobacco or cannabis?
In the United States, the products are regulated by the U.S. Food and Drug Administration (FDA) as tobacco products and some US states also regulate the products as cannabis products.
9. Has the company conducted consumer testing?
Yes. Consumer testing has been conducted to refine formulations and validate market interest.
10. Does the company operate any retail locations?
No. Distribution will occur through traditional wholesale and selected retail channels.
11. Does Cabbacis own patents?
Yes. The company holds 36 worldwide patents on its products.
12. What is covered by the patents?
Cigarettes and vaporizer pods with any combination very-low-nicotine tobacco and hemp.
13. Does the company license any technology?
Yes. Cabbacis in-licenses the proprietary very-low-nicotine tobacco it uses in its products from a major university,
14. What is the company’s IP strategy?
The company has built an international patent portfolio covering cigarettes and vaporizer pods with blends of tobacco and hemp.
15. Has Cabbacis conducted clinical studies?
Cabbacis contracted the Rose Research Center to carry out a pilot clinical trial on 16 smokers exclusively using four types of very-low-nicotine tobacco cigarettes made by Cabbacis during 3-hour ad libitum use sessions, which followed overnight abstinence from their usual brand cigarette. The nicotine content of all types was reduced by approximately 95 percent, as compared to the average of mainstream American brands. Three iBlend™ cigarette types contained very-low-nicotine tobacco and each type had a different level of hemp (5%, 10% and 20%), and the fourth cigarette type contained very-low-nicotine tobacco without any hemp.
16. What were the study results?
Participants across all four cigarette types reported a significant reduction in craving for their usual brand of cigarettes which was sustained over the 3-hours of ad libitum use of the study cigarettes. All four Cabbacis cigarette types were rated higher for satisfaction on the standardized mCEQ questionnaire than has been previously reported in the literature with other 95-percent reduced-nicotine cigarettes.
17. Does the company plan further studies?
Yes. The company is planning 2 follow-up behavioral studies and a consumer-perception study on iBlend™.
18. What market is Cabbacis targeting?
The global market for smoking and vaping alternatives.
19. What is the size of the total addressable market?
The global tobacco market exceeds $900 billion and the U.S. market exceeds $100 billion.
20. Who are the company’s competitors?
Traditional tobacco companies.
21. What makes Cabbacis different?
Patent-protected tobacco products with hemp which replicate the ritual and experience of smoking or vaping.
22. What is the company’s go-to-market strategy?
Upon commercialization, wholesale distribution, select retail partnerships and direct-to-consumer e-commerce.
23. What is being offered to investors?
Equity common shares in Cabbacis Inc (OTCQB: CABI) under a Regulation A (Tier 2) Offering.
24. Is this Offering qualified by the SEC?
Yes. The SEC qualified the Offering Circular on November 24, 2025.
25. What is the price per share?
$2.00 per share.
26. What is the minimum investment?
$1,000.
27. Who can invest?
Any U.S. resident over 18 can invest, subject to Regulation A limits. International investors may also participate.
28. Is there a maximum investment for some individuals?
Yes. Non-accredited investors are limited to 10 percent of their annual income or net worth, whichever is greater. There is no limit for accredited investors.
29. What is the maximum total raise?
Up to $7.5 million in gross proceeds.
30. Are shares freely tradeable after purchase?
Yes. Shares are listed on the OTCQB market under the symbol, CABI; however, the shares are currently very thinly traded.
31. Is the company profitable?
No. Cabbacis is a pre-revenue, early-stage company; however, the company has a very low burn rate, as shown in its publicly-available financial statements.
32. How will investor funds be used?
Assuming the Offering is fully subscribed and the company does not make an acquisition, the funds are expected to be for at least a 2-year period and will be used for G&A, R&D, Regulatory Expenses, Tobacco and Hemp Plantings, IP and machinery as detailed in the Offering Circular.
33. Are financial statements available?
Yes. Audited financial statements are included in the Offering Circular.
34. Will existing members or founders sell shares in this Offering?
No. All net proceeds go to the company. No insiders are selling shares.
35. Will investors receive updates?
Yes. Investors will receive periodic updates from the company via email and through the investment portal.
36. Will I receive dividends?
No. The company does not expect to pay dividends in the near term.
37. What type of legal entity is Cabbacis?
Cabbacis Inc (OTCQB: CABI) is a Nevada corporation and its wholly-owned operating company, Cabbacis LLC, is a New York company.
38. Will investors receive K-1s or 1099s?
The company does not expect to issue K-1s or 1099s.
39. Can I invest through an IRA, trust, or LLC?
Yes. Cabbacis may accept investments from self-directed IRAs, trusts, and other legal entities.
40. Can international investors participate?
Yes, where permitted under U.S. and local laws.
41. Will I have voting rights?
Investor rights are defined in the company’s governing documents. Regulation A investors may have limited governance rights.
42. How do I track my investment?
You will receive email confirmations and updates via the investment portal.
43. What is the expected holding period?
This is up to you, but please keep in mind that Cabbacis shares may be illiquid on the OTCQB market for an extended period of time.
44. Will my investment be listed in a brokerage account?
No. Shares are initially held electronically through the transfer agent or issuing platform.
45. Is this a crowdfunding campaign?
No. This is a Regulation A offering, not a Regulation CF (crowdfunding) raise.
46. Has Cabbacis raised money before?
Yes. The company has previously raised capital through private offerings and a Regulation A Offering that was qualified by the SEC in November 2023. The CEO has invested over $1.5 million in the company since inception.
47. Who do I contact with investment questions?
The investor relations team and platform support are available through the company’s investment portal.
48. Will I be diluted in the future?
Yes. Future equity financings would dilute existing investors.
49. Can I lose my entire investment?
Yes. This is a high-risk investment and may result in total loss of capital.
50. How is the $2.00 share price determined?
It reflects a pre-money valuation set by the company. It is not based on a third-party appraisal.
51. Are there commissions or fees for investors?
No commissions are charged directly to investors although commissions are charged for investments that go through the company’s investment bank. These and the offering expenses are paid by the company.
52. Is there a transfer agent?
Yes. A registered transfer agent manages investor records and share issuances.
53. Where can I read the Offering Circular?
It is available on the company’s investment portal and on SEC.gov under Cabbacis.
Ready to Invest?
Contact Us
Legal
This communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any offering of securities by Cabbacis Inc. is made pursuant to Regulation A under the Securities Act of 1933, as amended, and only through an offering circular that has been qualified by the U.S. Securities and Exchange Commission.
An offering circular relating to the securities has been filed with the SEC and includes important information about the Company, its business operations, financial condition, management, capitalization, use of proceeds, and material risk factors. Prospective investors should read the offering circular in its entirety before making any investment decision. In the event of any inconsistency between this communication and the offering circular, the information contained in the offering circular controls.
Investing in securities involves a high degree of risk, including the possible loss of all invested capital. There is no guarantee of any return, liquidity event, or future performance. Securities offered pursuant to Regulation A are speculative, illiquid, and not suitable for all investors. Past performance, if referenced, is not indicative of future results. Statements regarding future plans, expectations, or performance are forward-looking and subject to risks and uncertainties that could cause actual results to differ materially.
Neither the U.S. Securities and Exchange Commission nor any state securities regulator has approved or disapproved of these securities or passed upon the adequacy or accuracy of this communication. Any representation to the contrary is a criminal offense.
Copyright 2026. Cabbacis Inc.. All Rights Reserved.